Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings

There is high demand for diabetes and obesity medications known as glucagon-like peptide-1 agonists, or GLP-1s. In conjunction with an appropriate diet and exercise regimen, GLP-1s can provide substantial health benefits to patients. Prior to several GLP-1s becoming popular obesity therapeutics, the class of drugs had been in use for many years in the treatment of type 2 diabetes. And a GLP-1 named Wegovy (semaglutide) secured a supplemental cardiovascular indication from the Food and Drug Administration this spring.